The ultimate aim of the Avicenna action was to create a research and technological development Roadmap outlining a strategy for in silico Clinical Trials. The Roadmap describes the route by which in silico techniques of computer simulation will be introduced into clinical trials, the studies that are routinely conducted to establish the safety and efficacy of new medical interventions.
This action has engaged 525 experts from 35 countries, including 22 of the 28 members of the European Union, in an 18 month consensus process.
The Association for Predictive Medicine (Avicenna Alliance), is an association of industry and research organisations who have a commercial or research interest in in silico medicine. The Association, established in 2015, has its origins in the Virtual Physiological Human Initiative, a European Commission funded project focused on research into in silico medicine. Tasked by the European Commission with developing a “Roadmap for in silico medicine”, the Association now seeks to put this roadmap into policy and ensure the development of a regulated in silico market.